Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & PrecautionsAdditional Info
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Clarinex

[Desloratadine]

A male specific decrease in fertility, demonstrated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic testicular changes, occurred at an oral desloratadine dose of 12 mg/ kg in rats (estimated desloratadine exposures were approximately 45 times the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3 mg/ kg/ day (estimated desloratadine and desloratadine metabolite exposures were approximately 8 times the AUC in humans at the recommended daily oral dose).

Pregnancy Category C:

Desloratadine was not teratogenic in rats at doses up to 48 mg/ kg/ day (estimated desloratadine and desloratadine metabolite exposures were approximately 210 times the AUC in humans at the recommended daily oral dose) or in rabbits at doses up to 60 mg/ kg/ day (estimated desloratadine exposures were approximately 230 times the AUC in humans at the recommended daily oral dose). In a separate study, an increase in pre-implantation loss and a decreased number of implantations and fetuses were noted in female rats at 24 mg/ kg (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose).

Text Continues Below



Reduced body weight and slow righting reflex were reported in pups at doses of 9 mg/ kg/ day or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 50 times or greater than the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on pup development at an oral dose of 3 mg/ kg/ day (estimated desloratadine and desloratadine metabolite exposures were approximately 7 times the AUC in humans at the recommended daily oral dose).

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, desloratadine should be used during pregnancy only if clearly needed.

Page:  << Prev | 1 | 2 | 3 | Next >>







New Features

New ADHD Site!


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service